Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: KurtVedder who wrote (1119)	3/31/1998 3:13:00 PM
From: (no name provided)	Read Replies (2) \| Respond to of 1359

This is good news??? Every single treated group had a higher incidence of valvular disease. While not statistically significant on an individual basis, I suspect that the incidence of valvular disease overall is higher and statistically significant. Look at the numbers combined Treated with redux (5+1.7+6.5) = 13.2 Treated with sustained release (5.8 + 1.8 + 7.3) = 14.9 Placebo (3.6 + 1.2 + 4.5) = 9.3 And these were patients treated for only 77 days. Kafka666